After receiving approval for two HIV drugs, Delstrigo and Pifeltro, Merck should be expecting strong sales but probably unlikely to be at blockbuster levels, according to senior pharma analyst at GlobalData.
In this online exclusive, Rina Nir, managing director of RadBee, looks at why Agile and DevOps are the ultimate cure for pharma companies’ ailing computer systems validation process.
In this article with EPM, Dexter Tjoa, director of Corporate Strategy, discusses why outsourcing is fast becoming the most logical choice for companies who have delayed developing appropriate solutions and what benefits an experienced CPO can bring
Paolo Landriani, technical department director at SEA Vision, discusses the importance of the right equipment and software in this approach and how it can save space, improve quality and ultimately save manufacturers time and money.
Transparency Market Research has predicted that the global pharmaceutical robots market is set to witness high adoption of regional expansion, new product development and merger & acquisition as key business strategies, bagging $250.46m by 2026
A stark warning that ‘innovation is being hindered by regulators’ has been given by the president of EPCOT International, Girish Malhotra, in the first part of CPhI Worldwide’s sixth annual report.
In this interview, we at EPM magazine speak with Staffan Widengren, director of corporate projects at Recipharm on the difficulties CDMOs are facing leading up to the European Falsified Medicines Directive (EU FMD) deadline in February 2019.
According to poll results from Pew Research Center, the American public is accepting of gene editing in animals that could benefit human health, potentially removing a barrier to research, as noted by a pharma analyst at GlobalData.
Earlier this month (9 August) we passed the six-month time point before all companies in Europe will be expected to comply with the falsified medicines directive (FMD).
Here, Dr Sheuli Porkess, deputy chief scientific officer, Association of the British Pharmaceutical Industry (ABPI), outlines how the pharmaceutical industry takes a substance from molecule to medicine and how the process requires persistence.
In the latest annual snapshot of the manufacturing industry — published by the manufacturers’ organisation, EEF, and Santander — it has been shown that the sector contributes more than just the sum of its part.
